Tesamorelin
Several randomized clinical trials have shown the beneficial effects of
tesamorelin on impaired body composition in patients with HIV-associated
lipodystrophy [39-42]. A meta-analysis including four clinical
studies also revealed that tesamorelin decreased visceral fat and
increased lean body mass. As a result, the FDA approved tesamorelin
(Egrifta®) as the first-line treatment for reducing excess abdominal fat
in HIV-infected patients with lipodystrophy.